Xolair 150 MG/1.2 ML powder VLS
Ended Awarded
- Contract number
- SPE2DR26FDGG2
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,055
Award facts
- Contract value 100% obligated
- $11,054.54 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $11,054.54 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of XOLAIR 150 mg/1.2 mL powder vials. The contract, issued on October 22, 2025, with an ultimate completion date of November 13, 2025, utilizes firm fixed-price pricing with no set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the DLA's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion federal acquisition strategy that establishes multiple regional prime vendor contractors to support Department of Defense pharmaceutical supply requirements.
DMS Pharmaceutical Group operates as a critical supplier within the federal military medical supply chain, leveraging its small business status to compete effectively in unrestricted federal procurement. The company's IDC under PPV-G GEN V, designated contract SPE2DR, carries a ceiling value of $499.999 billion and extends through December 31, 2036, structured with a 30-month base period and three optional 30-month renewal periods. Under this contract vehicle, the DLA is authorized to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products including branded and generic prescription drugs, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide, with XOLAIR and similar specialty pharmaceutical products representing the specialized medical supply needs of Department of Defense operations.
Quick answers
Who was awarded contract SPE2DR26FDGG2?
SPE2DR26FDGG2 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 22, 2025.
How much is contract SPE2DR26FDGG2 worth?
The government has obligated $11,055 on SPE2DR26FDGG2.
Is contract SPE2DR26FDGG2 an order under another contract?
Yes. SPE2DR26FDGG2 is a delivery order under SPE2DR25D9151, an indefinite delivery contract.
Was contract SPE2DR26FDGG2 competed?
The extent of competition for SPE2DR26FDGG2 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award